Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...
Jun 27, 2025, 4:05 PM EDT - 4 weeks ago
May 21, 2025, 4:03 PM EDT - 2 months ago
May 8, 2025, 4:05 PM EDT - 2 months ago
May 1, 2025, 4:05 PM EDT - 3 months ago
Apr 7, 2025, 4:05 PM EDT - 4 months ago
Apr 3, 2025, 12:22 PM EDT - 4 months ago
Mar 17, 2025, 8:00 AM EDT - 4 months ago
Mar 13, 2025, 11:04 AM EDT - 4 months ago
Mar 13, 2025, 7:20 AM EDT - 4 months ago
Mar 3, 2025, 4:05 PM EST - 5 months ago
Mar 3, 2025, 1:32 PM EST - 5 months ago
Mar 3, 2025, 9:27 AM EST - 5 months ago
Mar 2, 2025, 11:00 AM EST - 5 months ago
Feb 27, 2025, 10:00 AM EST - 5 months ago
Feb 26, 2025, 10:00 AM EST - 5 months ago
Feb 25, 2025, 10:00 AM EST - 5 months ago
Feb 24, 2025, 10:00 AM EST - 5 months ago
Feb 23, 2025, 10:00 AM EST - 5 months ago
Feb 21, 2025, 10:00 AM EST - 5 months ago
Feb 20, 2025, 3:39 PM EST - 5 months ago
Feb 20, 2025, 10:00 AM EST - 5 months ago
Feb 19, 2025, 10:00 AM EST - 5 months ago
Feb 18, 2025, 10:00 AM EST - 5 months ago
Feb 17, 2025, 10:00 AM EST - 5 months ago
Feb 16, 2025, 10:00 AM EST - 5 months ago
Feb 14, 2025, 10:00 AM EST - 5 months ago